1190239-42-9
1190239-42-9
Chemical Structure
Fasinumab
Synonym(s): REGN475; SAR-164877
- CAS No.: 1190239-42-9
- Molecular Weight:(144.9 kDa)
SMILES: [Fasinumab]
Biological Activity: Fasinumab (REGN475) is a human IgG4 monoclonal antibody against nerve growth factor (NGF) that binds NGF and blocks its biological activity. Fasinumab is used in research on osteoarthritis and pain[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fasinumab | 98.11% | Fasinumab (REGN475) is a human IgG4 monoclonal antibody against nerve growth factor (NGF) that binds NGF and blocks its biological activity. Fasinumab is used in research on osteoarthritis and pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tiseo PJ, et al. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain. 2014 Jul;155(7):1245-1252.
- [2]. Bimonte S, et al. The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain. J Pain Res. 2021 Jun 28;14:1959-1967.
- [3]. Somersan-Karakaya S, et al. Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain. Neurobiol Pain. 2023 Jun 26;14:100136. [Content Brief]
